Cargando…
Antisense Oligonucleotide Therapeutic Approach for Suppression of Ataxin-1 Expression: A Safety Assessment
Spinocerebellar ataxia type 1 (SCA1) is a lethal, autosomal dominant neurodegenerative disease caused by a polyglutamine expansion in the ATAXIN-1 (ATXN1) protein. Preclinical studies demonstrate the therapeutic efficacy of approaches that target and reduce Atxn1 expression in a non-allele-specific...
Autores principales: | O’Callaghan, Brennon, Hofstra, Bente, Handler, Hillary P., Kordasiewicz, Holly B., Cole, Tracy, Duvick, Lisa, Friedrich, Jillian, Rainwater, Orion, Yang, Praseuth, Benneyworth, Michael, Nichols-Meade, Tessa, Heal, Wesley, Ter Haar, Rachel, Henzler, Christine, Orr, Harry T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452125/ https://www.ncbi.nlm.nih.gov/pubmed/32818920 http://dx.doi.org/10.1016/j.omtn.2020.07.030 |
Ejemplares similares
-
14-3-3 Binding to Ataxin-1(ATXN1) Regulates Its Dephosphorylation at Ser-776 and Transport to the Nucleus
por: Lai, Shaojuan, et al.
Publicado: (2011) -
The ataxin-1 interactome reveals direct connection with multiple disrupted nuclear transport pathways
por: Zhang, Sunyuan, et al.
Publicado: (2020) -
Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3
por: Toonen, Lodewijk J. A., et al.
Publicado: (2016) -
Allele-specific targeting of mutant ataxin-3 by antisense oligonucleotides in SCA3-iPSC-derived neurons
por: Hauser, Stefan, et al.
Publicado: (2021) -
Characterization of the Prion Protein Binding Properties of Antisense Oligonucleotides
por: Reidenbach, Andrew G., et al.
Publicado: (2019)